Abstract
Knowledge of the new European Union (EU) procedures is vital for pharmaceutical companies. This paper summarizes and comments upon the Draft Notice to Applicants, chapters II and III, which serve as a guide to the new procedures. This document draws from a variety of regulations that are referenced in the newly issued chapters with the goal of identifying key issues that require clarification. The conditions for a community referral as an independent procedure in addition to national, centralized, and decentralized procedures are also described.
Get full access to this article
View all access options for this article.
